ArticleInvestigational new drugs2020

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

W Larry Gluck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.